You are here: Industry Insights > SARS-CoV-2

News List

GenScript Receives EUA for Use of cPass SARS-CoV-2 Neutralization Antibody Test americanpharmaceuticalreview
February 24, 2021
GenScript has received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma ...
Deep Longevity Publishes Article About Preventing COVID-19 and Aging prnasia
February 20, 2021
Regent Pacific Group Limited's Deep Longevity, Inc. announced the publication of an article in Lancet Healthy Aging titled "The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19".
Experiment showed that Jemincare's neutralizing antibody JMB2002 would likely keep the potency against the South African mutant prnasia
February 09, 2021
On February 7, 2021, scientists from Jemincare Shanghai Research Institute published a preprint paper on BioRxiv, the paper entitled "A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed ...
How SARS-CoV-2 mutates to escape antibody binding worldpharmanews
February 08, 2021
In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the University of Pittsburgh School of Medicine.
Roche announces the upcoming launch of the SARS-CoV-2 Rapid Antigen Test Nasal allowing for patient self-collection worldpharmanews
February 07, 2021
Roche announced it has obtained the CE mark for its new SARS-CoV-2 Rapid Antigen Test Nasal. The test will be available in countries accepting the CE mark by mid-February 2021.
Hidrox(R), a proprietary olive polyphenols formulation may help in managing COVID-19 pandemic prnasia
February 07, 2021
Oliphenol LLC, Hayward, California, announces the publication of a discovery focused upon the SARS-CoV-2-inactivating activity of Hidrox®, an olive polyphenols formulation for a potential treatment against SARS-CoV-2 infection.
CureVac, UK Partner on Vaccines Against SARS-CoV-2 Variants contractpharma
February 07, 2021
Aims to mitigate the effects of the pandemic and help prepare against future SARS-CoV-2 outbreaks by working on multiple variant vaccines.
COVAXX Announces Phase 2 Clinical Trials of UB-612 Vaccine Candidate against COVID-19 americanpharmaceuticalreview
February 05, 2021
COVAXX has announced that the Taiwan, China Ministry of Health and Welfare on January 29, granted conditional approval to begin Phase 2 trials of UB-612, its vaccine candidate to address the pandemic caused by SARS-CoV-2.
Just, Evotec Expand mAbs Manufacturing Contract with DOD contractpharma
February 03, 2021
Evotec SE announced that the U.S. Department of Defense (DOD) awarded its Seattle, WA-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies (mAbs) for use in the development of a ...
Early functional SARS-COV-2 specific T cell response may prevent severe infection worldpharmanews
February 02, 2021
Humoral and cellular adaptive immunity are two immune mechanisms that act against pathogens. Humoral immunity is mediated by antibodies, while cellular immunity does not involve antibodies and is, instead, facilitated by T cells.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 61 62 Next page